[go: up one dir, main page]

WO2024182813A3 - Targeting alu rna to treat inflamation and related inflammatory diseases and conditions - Google Patents

Targeting alu rna to treat inflamation and related inflammatory diseases and conditions Download PDF

Info

Publication number
WO2024182813A3
WO2024182813A3 PCT/US2024/018437 US2024018437W WO2024182813A3 WO 2024182813 A3 WO2024182813 A3 WO 2024182813A3 US 2024018437 W US2024018437 W US 2024018437W WO 2024182813 A3 WO2024182813 A3 WO 2024182813A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
inflamation
treat
inflammatory diseases
related inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/018437
Other languages
French (fr)
Other versions
WO2024182813A2 (en
Inventor
Hana Totary-Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St Petersburg filed Critical University of South Florida
Publication of WO2024182813A2 publication Critical patent/WO2024182813A2/en
Publication of WO2024182813A3 publication Critical patent/WO2024182813A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are agents, compositions, and methods for use for preventing, inhibiting, or treating inflammation in a subject. The methods include using such agents, compositions for preventing, inhibiting, or treating conditions or diseases associated with inflammation.
PCT/US2024/018437 2023-03-02 2024-03-04 Targeting alu rna to treat inflamation and related inflammatory diseases and conditions Pending WO2024182813A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363487911P 2023-03-02 2023-03-02
US63/487,911 2023-03-02
US202363490753P 2023-03-16 2023-03-16
US202363490751P 2023-03-16 2023-03-16
US63/490,753 2023-03-16
US63/490,751 2023-03-16

Publications (2)

Publication Number Publication Date
WO2024182813A2 WO2024182813A2 (en) 2024-09-06
WO2024182813A3 true WO2024182813A3 (en) 2024-10-31

Family

ID=92590500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/018437 Pending WO2024182813A2 (en) 2023-03-02 2024-03-04 Targeting alu rna to treat inflamation and related inflammatory diseases and conditions

Country Status (1)

Country Link
WO (1) WO2024182813A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197207A1 (en) * 2010-06-01 2013-08-01 Universidty of Kentucky Research Foundation Method of inhibiting alu rna and therapeutic uses thereof
US20190262341A1 (en) * 2015-02-26 2019-08-29 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
WO2021178898A1 (en) * 2020-03-05 2021-09-10 Flagship Pioneering Innovations Vi, Llc Host defense suppressing methods and compositions for modulating a genome
US20210348164A1 (en) * 2018-10-09 2021-11-11 University Of Virginia Patent Foundation Endogenous cytoplasmic alu complementary dna in age-related macular degeneration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197207A1 (en) * 2010-06-01 2013-08-01 Universidty of Kentucky Research Foundation Method of inhibiting alu rna and therapeutic uses thereof
US20190262341A1 (en) * 2015-02-26 2019-08-29 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
US20210348164A1 (en) * 2018-10-09 2021-11-11 University Of Virginia Patent Foundation Endogenous cytoplasmic alu complementary dna in age-related macular degeneration
WO2021178898A1 (en) * 2020-03-05 2021-09-10 Flagship Pioneering Innovations Vi, Llc Host defense suppressing methods and compositions for modulating a genome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROMERO ROBERTO, MIRANDA JEZID, CHAIWORAPONGSA TINNAKORN, CHAEMSAITHONG PIYA, GOTSCH FRANCESCA, DONG ZHONG, AHMED AHMED I., YOON BO: "Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance", JOURNAL OF MATERNAL-FETAL AND NEONATAL MEDICINE, vol. 28, no. 11, 24 July 2015 (2015-07-24), UK , pages 1343 - 1359, XP093233138, ISSN: 1476-7058, DOI: 10.3109/14767058.2014.954243 *

Also Published As

Publication number Publication date
WO2024182813A2 (en) 2024-09-06

Similar Documents

Publication Publication Date Title
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MY196582A (en) PD-1/PD-L1 Inhibitors
EP4234030A3 (en) Pd-1/pd-l1 inhibitors
MX2023012981A (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use.
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
CL2021002878A1 (en) Treatment and prevention of metabolic diseases
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
MX2018007227A (en) Treatment of intrahepatic cholestasis and related liver diseases.
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
PH12023552830A1 (en) Compositions and methods for inhibiting ketohexokinase
UA89226C2 (en) Imidazole compounds
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MX2019013862A (en) Combination therapy.
MX2018012511A (en) Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors.
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
PH12022550130A1 (en) Enzyme inhibitors
PH12021552866A1 (en) Compositions and methods for treating cancer
WO2021038296A3 (en) Modified tff2 polypeptides
WO2020049552A9 (en) Tissue repair by activated cells
WO2023081500A3 (en) RNAi OLIGONUCLEOTIDE CONJUGATES
EP3781148A4 (en) Therapeutic methods and compositions for treating prostate cancer using 6,8-bis-benzylthio-octanoic acid
WO2019204332A3 (en) Pak4 inhibitors and methods of use
WO2024182813A3 (en) Targeting alu rna to treat inflamation and related inflammatory diseases and conditions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE